57806-76-5

Usage

Uses

Used in Insect Repellent Products:
DEET is utilized as an active ingredient in various insect repellent formulations for its ability to mask human scent, making it difficult for insects to detect and bite humans. It is particularly effective against mosquitoes, which are vectors for diseases such as malaria, dengue, and Zika virus.
Used in Outdoor and Recreational Activities:
DEET is commonly used by individuals engaging in outdoor and recreational activities, such as hiking, camping, and fishing, to protect against insect bites and reduce the risk of insect-borne diseases.
Used in Military and Field Operations:
Due to its proven efficacy and long-lasting protection, DEET is often used by military personnel and field workers operating in areas where insect-borne diseases are prevalent, ensuring their safety and reducing the risk of disease transmission.
Used in Public Health and Vector Control Programs:
DEET is incorporated into public health initiatives and vector control programs aimed at reducing the transmission of insect-borne diseases by providing personal protection to individuals in affected regions.
Used in Research and Development:
DEET serves as a reference compound in research and development efforts to create new and improved insect repellents with enhanced safety profiles, longer-lasting effects, and broader insect repelling capabilities.

InChI:InChI=1/C13H19NO/c1-5-14(6-2)13(15)12-9-7-8-10(3)11(12)4/h7-9H,5-6H2,1-4H3

Upstream product

• 109-89-7 diethylamine 
• 603-79-2 2,3-dimethylbenzoic acid 
• 1018818-13-7 4-[(2R,4R)-4-hydroxy-2-hydroxymethylpyrrolidin-1-yl]butyronitrile 
• 1018818-07-9 3-[(2R,4S)-2-hydroxymethyl-4-methylpyrrolidin-1-yl]propionitrile 
• 1018818-03-5 3-[(2S,4R,5R)-4,5-dimethyl-2-hydroxymethylpyrrolidin-1-yl]propionitrile 
• 1018817-99-6 3-(5-ethyl-2-hydroxymethyl-3-methylpyrrolidin-1-yl)propionitrile 

Downstream Products

• 680223-81-8 (+/-)-3-(1-benzylpyrrolidin-3-yl)-5-methyl-2H-isoquinolin-1-one 
• 680223-74-9 (R)-N,N-diethyl-2-[4-(3-hydroxypyrrolidin-1-yl)-2-oxobutyl]-3-methylbenzamide 
• 1617529-35-7 benzyl-[3-(1,5-dimethyl-1H-pyrrol-2-yl)-5-methyl-isoquinolin-1-yl]-amine 
• 1617529-30-2 5-methyl-3-thiophen-2-yl-2H-isoquinolin-1-one 
• 1454901-02-0 3-(4-bromophenyl)-5-methyl-2H-isoquinolin-1-one 

Relevant academic research and scientific papers

α-C-H/N-H Annulation of Alicyclic Amines via Transient Imines: Preparation of Polycyclic Lactams

Polycyclic lactams are prepared in a single operation from o-toluamides and cyclic amines in a process that involves transient cyclic imines, species that are conveniently obtained in situ from the corresponding lithium amides and simple ketone oxidants. Imines thus generated, such as 1-pyrroline and 1-piperideine, engage lithiated o-toluamides in a facile annulation process. Undesired side reactions such as imine deprotonation and o-toluamide dimerization are suppressed through the judicious choice of reaction conditions.

3-ARYL-5-SUBSTITUTED-ISOQUINOLIN-1-ONE COMPOUNDS AND THEIR THERAPEUTIC USE

The present invention pertains generally to the field of therapeutic compounds. More specifically the present invention pertains to certain 3-aryl-5-substituted-2H-isoquinolin-1-one compounds that, inter alia, inhibit PARP (e.g., PARP1, TNKS1, TNKS2, etc.

Design and discovery of 3-aryl-5-substituted-isoquinolin-1-ones as potent tankyrase inhibitors

The tankyrase proteins (TNKS, TNKS2), members of the PARP superfamily of enzymes, are attractive anti-cancer drug targets, particularly as inhibition of their catalytic activity has been shown to antagonise oncogenic WNT signalling. To identify chemical inhibitors of tankyrase we carried out an in silico small molecule screen using a set of 'PARP-binding' pharmacophores together with a generated (liganded) tankyrase homology model. This approach identified a structurally diverse set of ～1000 compounds for further study. Subsequent in vitro screening of recombinant tankyrase protein identified a subset of 59 confirmed inhibitors. Early optimisation followed by cell-based studies in WNT-dependent tumour cells, as well as co-crystallisation studies, identified a novel class of 3-aryl-5-substituted isoquinolin-1-ones, such as 21, that exhibit potent inhibition of tankyrase activity as well as growth inhibition of colorectal cancer cells.

Isoquinoline compound and pharmaceutical use thereof

The present invention relates to an isoquinoline compound represented by the following formula (I), an optically active form thereof, a pharmaceutically acceptable salt thereof, a water adduct thereof, a hydrate thereof and a solvate thereof, as well as an agent for the prophylaxis and/or treatment of a disease caused by hyperreactivity of poly(ADP-ribose)polymerase, containing the compound, and a poly(ADP-ribose)polymerase inhibitor containing the compound. In addition, this compound is useful as an agent for the prophylaxis and/or treatment of cerebral infarction, particularly as an agent for the prophylaxis and/or treatment of acute cerebral infarction. Furthermore, this compound is useful as a prophylactic and/or therapeutic agent that improves neurological symptoms associated with cerebral infarction, particularly acute cerebral infarction. wherein the symbols are the same as defined in the description.